Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Michigan Rogel Cancer Center
Study ID
NCT03242915
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    200mg IV every 3 weeks
  • Carboplatin — DRUG
    AUC 5 IV every 3 weeks
  • Pemetrexed — DRUG
    500 mg/m\^2 IV every 3 weeks

Study Details

Investigators hypothesize that addition of pembrolizumab will enhance the efficacy of carboplatin and pemetrexed in patients with EGFR-mutation-positive NSCLC, or patients with other genetic alterations, and who have disease progression following appropriate targeted therapies.

Key Dates

Start date
Oct 3, 2017
Status verified
May 2025
Primary completion
Feb 20, 2025
Completion
Feb 20, 2025

Study Design

Enrollment
33 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab/Carboplatin/Pemetrexed
    Pembrolizumab 200 mg with carboplatin at AUC (area under the curve dosing) 5 and pemetrexed at 500 mg/m2 administered intravenously every 3 weeks

Primary Outcome Measure

The Percentage of Patients That Respond to Treatment [ Time Frame: 5.5 years ]

Locations (7)

FacilityCityStateZIPSite coordinators
Rush University Medical CenterChicagoIllinois60612-
The University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109-
Barbara Ann Karmanos Cancer InstituteDetroitMichigan48201-
Henry Ford Cancer Institute/Henry Ford HospitalDetroitMichigan48202-
Montefiore Cancer CenterThe BronxNew York10467-
Cleveland ClinicClevelandOhio44195-
Sarah CannonNashvilleTennessee37203-

Related coverage on Hipa.ai

Find similar trials in Chicago, IL

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Rush University Medical Center· Chicago, ILThe University of Michigan Comprehensive Cancer Center· Ann Arbor, MIBarbara Ann Karmanos Cancer Institute· Detroit, MIHenry Ford Cancer Institute/Henry Ford Hospital· Detroit, MIMontefiore Cancer Center· The Bronx, NYCleveland Clinic· Cleveland, OH

Related Studies